USNA or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of USANA Health Sciences (USNA) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • May 12, 2026

Should Value Investors Buy USANA Health Sciences (USNA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • May 8, 2026

USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock?

USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • May 8, 2026

USANA's People-First Culture Earns Spot on USA TODAY Top Workplaces List

SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- USANA Health Sciences (NYSE: USNA), a global leader in cellular nutrition, is proud to announce it has earned a spot on the prestigious 2026 USA TODAY Top Workplaces award list. The award honors organizations with 150 or more employees that have created exceptional, people-first cultures.

PRNewsWire • May 7, 2026

USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript

USANA Health Sciences, Inc. (USNA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

USANA Health Sciences Reports First Quarter 2026 Results

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Act.

Business Wire • May 5, 2026

USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates

USANA Health Sciences (USNA) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.73 per share a year ago.

Zacks Investment Research • May 6, 2026

During National Show Your Smile Month, Kevin Guest Urges Leaders to Lift Others Daily

SALT LAKE CITY, May 1, 2026 /PRNewswire/ -- During May's National Show Your Smile Month, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE: USNA), is calling on leaders to use one of the most overlooked tools in business and life: a genuine smile. "Smiling isn't surface-level," said Kevin Guest.

PRNewsWire • May 1, 2026

One Capsule, Endless Glow--Radiant Skin Starts Within

Introducing Glow ™ , USANA's first skin supplement SALT LAKE CITY, April 27, 2026 /PRNewswire/ -- USANA Health Sciences (NYSE: USNA), a global leader in cellular nutrition, proudly announces the launch of Glow, an innovative skincare supplement designed to support radiant, even-toned skin from within.* Glow represents a new frontier for USANA—moving beyond topical solutions to address skin health at the cellular level.

PRNewsWire • Apr 27, 2026

Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Apr 20, 2026